Pacer Advisors
CUE icon

Pacer Advisors’s Cue Biopharma CUE Stock Holding History

Pacer Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-51
Closed -$19K – 1444
2021
Q1 		$19K Sell
51
-10
-16% -$4.12K ﹤0.01% 1508
2020
Q4 		$23K Buy
61
+28
+85% +$11.2K ﹤0.01% 1476
2020
Q3 		$15K Buy
+33
New +$19K ﹤0.01% 1365

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pacer Advisors's CUE Position: Q2 2021 in Review

Pacer Advisors sold out of Cue Biopharma (CUE) in Q2 2021, closing a stake of 51 shares — an estimated $19K sold.

Pacer Advisors first reported a position in CUE in Q3 2020 and held it in 3 quarters. The position peaked at $23K in Q4 2020. 89 funds tracked by Wall St. Rank hold CUE as of Q2 2021.

  • Pacer Advisors reported no remaining Cue Biopharma position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 51 Cue Biopharma shares in Q2 2021, an estimated $19K.
  • Pacer Advisors first reported a position in Cue Biopharma in Q3 2020 and held it in 3 quarters.
  • Pacer Advisors's Cue Biopharma position peaked at $23K in Q4 2020.
  • 89 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.